Key clinical point: Combination of decitabine and human leukocyte antigen-mismatched hematopoietic stem cell microtransplantation (HLA-MST) could be an effective and safe treatment in patients with intermediate- or high-risk myelodysplastic syndrome (MDS).
Major finding: Overall survival was significantly higher in the decitabine and HLA-MST combination vs. decitabine alone group (24.00 vs. 14.13 months; hazard ratio, 0.32; P = .04). The incidence of hematological adverse events except thrombocytopenia and nonhematological adverse events was slightly lower in decitabine+HLA-MST vs. decitabine alone group.
Study details : Findings are from a retrospective study of 22 patients with intermediate- or high-risk MDS who were treated with decitabine (n=11) or decitabine and HLA-MST combination (n=11).
Disclosures: The study was funded by National Natural Science Foundation of China; the Science and Technology Planning Project of Guangdong Province, China; the Guangzhou Regenerative Medicine and Health Guangdong Laboratory; and the Project of Guangdong Province Traditional Chinese Medicine Bureau. The authors declared absence of any commercial or financial relationships during conduct of the study.
Source: Li MM et al. Front Oncol. 2021 Mar 31. doi: 10.3389/fonc.2021.628127 .